Sanofi and Jennifer Doudna-Founded Scribe ink $1B CRISPR cell therapy deal R&D, Therapeutics Sanofi has inked a licensing deal with Scribe Therapeutics to develop novel natural killer (NK) cell therapies for cancer using Scribe’s CRISPR genome editing technology. Read more September 27, 2022/by BioSpace https://www.pharmalive.com/wp-content/uploads/2022/03/Adagene-and-Sanofi-Tie-Up-in-2.5B-Antibody-Collab-BioSpace-3-2-22.jpeg 350 625 BioSpace https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png BioSpace2022-09-27 10:19:112022-09-27 10:20:13Sanofi and Jennifer Doudna-Founded Scribe ink $1B CRISPR cell therapy deal
